Chronic airflow limitation and its relation to respiratory symptoms among ever-smokers and never-smokers: a cross-sectional study.
clinical epidemiology
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
20
03
2020
revised:
29
06
2020
accepted:
03
07
2020
entrez:
8
8
2020
pubmed:
8
8
2020
medline:
11
6
2021
Statut:
ppublish
Résumé
The diagnosis of chronic obstructive pulmonary disease is based on the presence of persistent respiratory symptoms and chronic airflow limitation (CAL). CAL is based on the ratio of forced expiratory volume in 1 s to forced vital capacity (FEV In a cross-sectional study comprising 15 128 adults (50-64 years), 7120 never-smokers and 8008 ever-smokers completed a respiratory questionnaire and performed FEV Among all subjects, regardless of smoking habits, the odds of The association between percentages of FEV
Sections du résumé
BACKGROUND
The diagnosis of chronic obstructive pulmonary disease is based on the presence of persistent respiratory symptoms and chronic airflow limitation (CAL). CAL is based on the ratio of forced expiratory volume in 1 s to forced vital capacity (FEV
METHODS
In a cross-sectional study comprising 15 128 adults (50-64 years), 7120 never-smokers and 8008 ever-smokers completed a respiratory questionnaire and performed FEV
RESULTS
Among all subjects, regardless of smoking habits, the odds of
CONCLUSIONS
The association between percentages of FEV
Identifiants
pubmed: 32759170
pii: 7/1/e000600
doi: 10.1136/bmjresp-2020-000600
pmc: PMC7409993
pii:
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: AA reports personal fees from Novartis and AstraZeneca, outside this work. AL reports personal fees from Boehringer Ingelheim, AstraZeneca, Novartis and Active Care, outside the submitted work. JV reports personal fees from Boehringer Ingelheim, outside the submitted work. PW reports personal fees from AstraZeneca and Chiesi Pharmaceuticals, outside the submitted work. CMS reports personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, AstraZeneca, Roche and Genzyme, outside the submitted work. PW has a patent device and method for pulmonary capacity measurements issued. MS reports personal fees from AstraZeneca, outside the submitted work.
Références
Respir Med. 2009 Oct;103(10):1468-76
pubmed: 19464159
Thorax. 2014 Aug;69(8):709-17
pubmed: 24706040
Thorax. 1999 Jul;54(7):581-6
pubmed: 10377201
Am J Respir Crit Care Med. 2012 Feb 15;185(4):435-52
pubmed: 22336677
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Eur Respir J. 2019 May 18;53(5):
pubmed: 30846476
Prim Care Respir J. 2012 Sep;21(3):295-301
pubmed: 22786813
Chronic Obstr Pulm Dis. 2019 Nov;6(5):384-399
pubmed: 31710793
Chest. 2006 Nov;130(5):1319-25
pubmed: 17099006
Int J Chron Obstruct Pulmon Dis. 2016 May 02;11:927-33
pubmed: 27194908
J Clin Epidemiol. 2006 Jan;59(1):90-3
pubmed: 16360566
Clin Physiol Funct Imaging. 2017 Nov;37(6):640-645
pubmed: 26865107
Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76
pubmed: 11316667
Am J Respir Crit Care Med. 2017 Jan 1;195(1):17-22
pubmed: 27598473
JAMA. 2019 Jun 25;321(24):2438-2447
pubmed: 31237643
Chest. 2011 Apr;139(4):752-763
pubmed: 20884729
Am J Respir Crit Care Med. 2010 Mar 1;181(5):446-51
pubmed: 20019341
J Clin Epidemiol. 1990;43(1):109-13
pubmed: 2319275
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
J Intern Med. 2015 Dec;278(6):645-59
pubmed: 26096600
Thorax. 2005 Oct;60(10):842-7
pubmed: 16085729
Eur Respir J. 2019 Sep 19;54(3):
pubmed: 31248954
Thorax. 2012 Jul;67(7):569-70
pubmed: 22467708
N Engl J Med. 2016 May 12;374(19):1811-21
pubmed: 27168432
Proc Am Thorac Soc. 2005;2(4):267-71; discussion 290-1
pubmed: 16267347
Scand J Public Health. 2017 Jul;45(17_suppl):45-49
pubmed: 28683666
Respir Med. 2018 Nov;144:36-41
pubmed: 30366582
Thorax. 2019 Oct;74(10):958-964
pubmed: 31434752
Lancet Respir Med. 2013 Sep;1(7):543-50
pubmed: 24461615
Chronic Obstr Pulm Dis. 2019 Nov;6(5):380-383
pubmed: 31710794
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582
pubmed: 28128970
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
BMC Pulm Med. 2020 Feb 27;20(1):55
pubmed: 32106839